APLI Stock Overview
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Appili Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.045 |
| 52 Week High | CA$0.08 |
| 52 Week Low | CA$0.025 |
| Beta | 1.15 |
| 1 Month Change | 28.57% |
| 3 Month Change | 28.57% |
| 1 Year Change | 28.57% |
| 3 Year Change | -95.59% |
| 5 Year Change | n/a |
| Change since IPO | -94.38% |
Recent News & Updates
Shareholder Returns
| APLI | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | -8.9% | -1.5% |
| 1Y | 28.6% | 49.0% | 4.7% |
Return vs Industry: APLI underperformed the Canadian Pharmaceuticals industry which returned 49% over the past year.
Return vs Market: APLI exceeded the Canadian Market which returned 4.7% over the past year.
Price Volatility
| APLI volatility | |
|---|---|
| APLI Average Weekly Movement | 26.5% |
| Pharmaceuticals Industry Average Movement | 14.3% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.4% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: APLI's share price has been volatile over the past 3 months.
Volatility Over Time: APLI's weekly volatility (27%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 9 | Don Cilla | www.appilitherapeutics.com |
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
Appili Therapeutics Inc. Fundamentals Summary
| APLI fundamental statistics | |
|---|---|
| Market cap | CA$5.46m |
| Earnings (TTM) | -CA$5.34m |
| Revenue (TTM) | CA$1.15m |
4.7x
P/S Ratio-1.0x
P/E RatioIs APLI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APLI income statement (TTM) | |
|---|---|
| Revenue | CA$1.15m |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$1.15m |
| Other Expenses | CA$6.49m |
| Earnings | -CA$5.34m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.044 |
| Gross Margin | 100.00% |
| Net Profit Margin | -464.23% |
| Debt/Equity Ratio | -81.5% |
How did APLI perform over the long term?
See historical performance and comparison